| [1] |
O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging [J]. J Natl Cancer Inst, 2004, 96(19): 1420-1425.
|
| [2] |
Khattak MA, Martin HL, Beeke C, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer [J]. Clin Colorectal Cancer, 2012, 11(4): 247-254.
|
| [3] |
Baek SJ, Hur H, Min BS, et al. The characteristics of bone metastasis in patients with colorectal cancer: A long-term report from a single institution [J]. World J Surg, 2016, 40(4): 982-986.
|
| [4] |
Li A, Käsmann L, Rades D, et al. A scoring system to predict the development of bone metastasis after radical resection of colorectal cancer [J]. Anticancer Res, 2017, 37(9): 5169-5172.
|
| [5] |
Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile [J]. Dis Colon Rectum, 1999, 42(12): 1592-1597.
|
| [6] |
Katoh M, Unakami M, Hara M, et al. Bone metastasis from colorectal cancer in autopsy cases [J]. J Gastroenterol, 1995, 30(5): 615-618.
|
| [7] |
Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer [J]. Clin Colorectal Cancer, 2005, 5(2): 108-113.
|
| [8] |
Kawamura H, Yamaguchi T, Yano Y, et al. Characteristics and prognostic factors of bone metastasis in patients with colorectal cancer [J]. Dis Colon Rectum, 2018, 61(6): 673-678.
|
| [9] |
Robinson JR, Newcomb PA, Hardikar S, et al. Stage IV colorectal cancer primary site and patterns of distant metastasis [J]. Cancer Epidemiol, 2017, 48: 92-95.
|
| [10] |
Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis: recent comparative studies of imaging modalities [J]. Q J Nucl Med Mol Imaging, 2011, 55(4): 374-410.
|
| [11] |
Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases [J]. Q J Nucl Med, 2001, 45(1): 53-64.
|
| [12] |
Lecouvet FE, Talbot JN, Messiou C, et al. Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the European organisation for research and treatment of cancer imaging group [J]. Eur J Cancer, 2014, 50(15): 2519-2531.
|
| [13] |
Stecco A, Trisoglio A, Soligo E, et al. Whole-body MRI with diffusion-weighted imaging in bone metastases: A narrative review [J]. Diagnostics (Basel), 2018, 8(3): 45.
|
| [14] |
Samarin A, Hüllner M, Queiroz MA, et al. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT [J]. Nucl Med Commun, 2015, 36(12): 1165-1173.
|
| [15] |
Skougaard K, Nielsen D, Jensen BV, et al. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab [J]. J Nucl Med, 2013, 54(7): 1026-1031.
|
| [16] |
Senaratne SG, Colston KW. Direct effects of bisphosphonates on breast cancer cells [J]. Breast Cancer Res, 2002, 4(1): 18-23.
|
| [17] |
Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines [J]. Br J Cancer, 2000, 82(8): 1459-1468.
|
| [18] |
Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases [J]. Cancer Res, 2000, 60(11): 2949-2954.
|
| [19] |
Lopez-Olivo MA, Shah NA, Pratt G, et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis [J]. Support Care Cancer, 2012, 20(11): 2985-2998.
|
| [20] |
Liu J, Huang W, Zhou R, et al. Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: A meta-analysis [J]. Medicine (Baltimore), 2015, 94(46): e2014.
|
| [21] |
Tokito T, Shukuya T, Akamatsu H, et al. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases [J]. Cancer Chemother Pharmacol, 2013, 71(6): 1493-1498.
|
| [22] |
杨宇晨，汪佼佼，张敬东, 等. 西妥昔单抗治疗RAS野生型结肠癌骨髓转移二例 [J/CD]. 中华结直肠疾病电子杂志, 2018, 7(5): 482-484.
|
| [23] |
Jabbari S, Gerszten PC, Ruschin M, et al. Stereotactic body radiotherapy for spinal metastases: practice guidelines, outcomes, and risks [J]. Cancer J, 2016, 22(4): 280-289.
|
| [24] |
Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial [J]. Lancet Oncol, 2012, 13(4): 395-402.
|
| [25] |
Nguyen J, Chow E, Zeng L, et al. Palliative response and functional interference outcomes using the brief pain inventory for spinal bony metastases treated with conventional radiotherapy [J]. Clin Oncol (R Coll Radiol), 2011, 23(7): 485-491.
|
| [26] |
Choi J, Lee EJ, Yang SH, et al. A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers [J]. J Radiat Res, 2019, 60(2): 242-248.
|
| [27] |
Zhao W, Wang H, Hu JH, et al. Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis [J]. Jpn J Clin Oncol, 2018, 48(8): 753-759.
|